NEO1

Across TCGA pan-cancer cohorts, NEO1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NEO1 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher NEO1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEO1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUSC, UCEC, and KIRC are the cancer types where NEO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.374	0.754	<.001	62	view →
UCEC	DFS	Median	II,III,IV	0.910	0.295	.003	28	view →
KIRC	DFS	Median	All	0.266	0.796	.020	6	view →
BLCA	OS	Median	II,III,IV	0.901	0.408	.030	6	view →
LUAD	OS	Median	III,IV	0.158	0.660	.019	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →
PRAD	DFS	Median	All	0.164	0.777	<.001	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NEO1–LUSC (OS)

Open the LUSC breakdown →